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SUMMARY 
 
   Introduction: The aim of this paper was to assess early toxicity and feasibility of concomitant radio-
chemotherapy in the treatment of locally advanced cervical cancer in daily routine clinical practise. 
   Material and methods: Between 1st of May 2000 and 15th of November 2000, twenty one patients 
suffering from stage IIB and IIIB (FIGO classification) cervical carcinoma were treated in the Radio-
therapy Department of the Holycross Cancer Centre by concomitant radio-chemotherapy. Early 
toxicity of the skin, the lower gastrointestinal system and the genitourinary system was assessed 
according to acute radiation morbidity scoring criteria EORTC/RTOG. Leukopenia, thrombocytopenia, 
anemia, nausea, vomiting and nephrotoxicity were scored according to the WHO scale. 
   Results: There were no treatment-related deaths and no treatment breaks in radiotherapy due 
to acute toxicity. Only 48% of patients completed all 6 courses of cis-platin. The main causes 
of withdrawals from consecutive cycles of chemotherapy were: leucopenia - grade 2 or 3, throm-
bocytopenia - grade 3 and patient refusal. One patient developed acute renal failure. Other adverse 
effects did not exceed grade 2. 
   Conclusions: Concomitant radio-chemotherapy in the treatment of locally advanced cervical cancer 
was feasible and featured acceptable toxicity. Haematologic adverse effects were the main reasons 
of discontinued chemotherapy. Radiotherapy was well tolerated and all patients completed the whole 
course.   
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INTRODUCTION 
 
   Cervical cancer is the second most 
frequent cancer among women in Poland 
[1]. Despite screening programmes 
the rate of locally advanced stage patients 
is still high in our country, amounting 
to about 30% of all treated women. 
Concomitant radio-chemotherapy in the tre-
atment of locally advanced cervical cancer 
was implemented in the Holycross Cancer 
Centre as a result of better outcome 
obtained in randomised III-phase trials 
published in 1999 [2,3,4,5,6]. The weekly 
intravenous infusion of cis-platin con-
comitant with radiotherapy was chosen 
because it proved to be less toxic than 
multiagent chemotherapy [2,7]. The aim 
of this paper was to assess early toxicity 
and feasibility of this method of treatment 
in daily routine clinical practise. 
 
MATERIAL AND METHODS 
 
   Between 1st of May 2000 and 15th 
of November 2000 twenty one patients 
suffering from an advanced stage cervical 
carcinoma were treated in the Radio-
therapy Department of the Holycross Can-
cer Centre with concomitant radio-chemo-
therapy. There were 12 IIB and 9 IIIB 
patients (FIGO classification). Qualification 
and stage assessment were made 
by a multidisciplinary team of physicians 
consisting of: a radiation oncologist, gyna-
ecologist and clinical oncologist. In the first
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phase of the treatment teleradiotherapy 
was combined with cis-platin 40 mg/m2 
administered intravenously on 1,8,15,22, 
29,36 days of therapy. Chemotherapy was 
carried out along with standard adjunctive 
treatment (antiemetic prophylaxis and hy-
dration with forced diuresis). Treatment 
with cis-platin was discontinued if the leu-
kocyte count dropped below 3000 per 
cubic millimetre, or the platelet count 
dropped below 100 000 per cubic milli-
metre or creatinine level above 1.5 mg/dl. 
Teleradiotherapy was delivered with 
the standard four field isocentric box 
technique with 15-MV photons with pa-
tients lying prone. The pelvic field 
extended from the upper margin of L5 
to the lower portion of the obturator 
foramen or the lowest level affected by 
the disease, with 3-cm margin, and late-
rally, 1.5-2 cm beyond the lateral margins 
of the bony pelvic wall. For the lateral 
fields, the anterior border was the midsym-
physis of the pubic bone and the posterior 
border was the space between S2 and S3. 
Fractions of 1.8 Gy were delivered five 
days a week with a total dose of 50.4 Gy 
(calculated at a reference point according 
to ICRU 50). LDR/MDR (Cs-137) brachy-
therapy was performed in two or three 
intracavitary applications, 7 to 14 days 
after the completion of pelvic radiotherapy. 
The total dose was calculated at point 
A and varied from 25.31 Gy to 45.08 Gy, 
depending on the dose given to the organs 
at risk (bladder and rectum). The brachy-
therapy fractions were delivered in one 
a week intervals. Early toxicity of the skin, 
the lower gastrointestinal system and 
the genitourinary system was assessed 
according to acute radiation morbidity 
scoring criteria EORTC/RTOG. Leukope-
nia, thrombocytopenia, anaemia, nausea, 
vomiting and nephrotoxicity were scored 
according to the WHO scale. 
 
RESULTS 
 
   There were no treatment-related deaths 
and no treatment breaks in radiotherapy 
due to acute toxicity. Ten patients 
completed all 6 courses of cis-platin 
(48%), 4 patients received 5 cycles (19%), 
two patients had 4 cycles (9%), 2 patients 
had 3 cycles (9%), one patient had two 
cycles (5%) and two patients received only 
one cycle (9%) (Fig. 1). The main causes 
of withdrawals from a consecutive cycles 
of chemotherapy were: leucopenia- grade 
2 or 3 in 9 patients (42%) (Fig. 2), throm-
bocytopenia- grade 3 in 2 patients (10%) 
and patient’s refusal of the next course of 
chemotherapy in 2 cases (10%). In 4 pa-
tients with leucopenia, growth factors were 
used after the 3rd, 4th, 5th and 6th course 
of cis-platin respectively. Anaemia grade 
3 occurred in one patient (5%) but she had 
an episode of bleeding from the tumour 
during treatment which required blood 
transfusion. One patient developed acute 
renal failure after the 1st cycle of cis-platin, 
but she continued radiation without che-
motherapy. Nausea and vomiting were 
observed, but they were grade 1 and did 
not effect the treatment breaks. The adver-
se effects in the gastrointestinal and geni-
tourinary systems were grade 1 and 2 and 
were observed in 11 (51%) and 9 (42%) 
patients respectively. The early skin toxi-
city was grade 1 and was noticed only 
in two patients in the perineal region in wo-
men who had their field border below 
the obturator foramen. 
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Fig. 1. Number of chemotherapy courses given to patients.
Fig. 2. Leucopenia according to the who scale.
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DISCUSSION 
 
   Combined radiotherapy and chemo-
therapy that include cisplatin improve 
the clinical outcome in women with locally 
advanced cervical cancer [2,3,4,5,6,7,8]. 
Also, the addition of cisplatin-based 
chemotherapy to adjuvant irradiation 
significantly improves the survival for high-
risk, early stage patients who undergo 
radical hysterectomy and pelvic lympha-
denectomy for carcinoma of the cervix [9]. 
Such an intensification of the treatment 
compared with the previously used stan-
dard radiotherapy carries a higher risk 
of severe toxicity which may question 
the feasibility of the combine treatment 
in the Polish population. In our group 
of patients we did not observe treatment- 
related deaths and all patients completed 
the whole course of radiotherapy. In a re-
cently published series more than 90% 
of patients completed the whole course 
of irradiation [2,3,4,5,9]. Of 21 evaluated 
patients, 48% completed the whole six 
courses of cis-platin, which is similar 
to chemotherapy compliance reported 
in a randomised trial where the same 
chemotherapy regimen was used in an ap-
proximately same group of patients [2]. 
Only 76% of our patients completed four 
or more courses of chemotherapy, which 
is less successful than one of the public-
shed series where over 90% completed 
more than half of the chemotherapy [2,4], 
although we used growth factors in the tre-
atment of the leucopenia in 4 of our pa-
tients in the second half of the treatment. 
We cannot find any reason to explain this 
fact, it may have happened because we 
were over-cautious and withheld cis-platin 
if the leukocyte and platelet count fell 
below the level higher than that used 
in a randomised setting [2]. Additionally, 
there were 10% of patients who refused 
to continue chemotherapy in the early 
stage of the treatment. The main reason 
of the discontinued chemotherapy and 
principal adverse effects was haematolo-
gic toxicity, mainly leucopenia grade 
2 or higher, observed in 42% and in 49% 
of patients in our study and in the rando-
mised study [2], respectively. Thrombo-
cytopenia grade 2 or higher appeared less 
frequently and was observed in 9% of our 
patients and 6% in the published study [2]. 
Using a similar regimen in the bulky stage 
IB, haematologic toxicity grade 2 or higher 
was observed in 57% of the patients [4]. 
The gastrointestinal (GI) and genitourinary 
(GU) grade 1 or 2 toxicity were observed 
in approximately half of our patients and 
did not cause any breaks of the treatment. 
In two randomised studies using the same 
cis-platin schedule, moderate GI toxicity 
was at the same level, the only difference 
was in the occurrence of life-threatening 
grade 3 and 4 in about 10% of all patients 
[2,4], which was not observed in our 
patients. The explanation of this fact may 
lie in the smaller average number of cis-
platin courses received by our patients. 
The same cause may have led to the lack 
of severe GU toxicity in our study. 
The other toxicity was of a mild grade or, 
if se-vere, it appeared very rarely [2,4].  
   The cis-platin based concomitant radio-
chemotherapy, despite enhanced toxicity, 
is feasible but about half of the patients 
failed to complete the whole course of tre-
atment. Due to minor deviations from 
the treatment plan the use of growth 
factors in selective cases may have incre-
ased the rate of given cycles of the che-
motherapy and lessened the haematologic 
toxicity. Another way to achieve this goal 
was to use a less intensive chemotherapy 
with the same survival benefit and less 
toxicity. In recently published preliminary 
results of a randomised trial using 
concomitant treatment with mitomycin C 
showed therapeutic enhancement 
compared with radiotherapy alone 
accompanied by very mild haematologic 
toxicity and no excess in the non-
haematologic adverse effects [10]. 
 
CONCLUSIONS 
 
   Concomitant radio-chemotherapy 
in the treatment of locally advanced 
cervical cancer was feasible and led 
to acceptable toxicity. Haematologic 
adverse effects constituted the main 
reasons of discontinued chemotherapy. 
Radiotherapy was well tolerated and all 
patients completed the whole course. 
Early toxicity presented in this paper was 
basically similar to the results published by 
other authors. It is necessary to continue 
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observation of the patients in order 
to assess late toxicity and long-term 
results of combined radio-chemotherapy 
treatment.            
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